Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma.
PMID 19789534 · PMC2768081 · British journal of cancer · 2009 · 8 claims · 7 setups
Cathepsin D, identified via comparative 2D PAGE of conditioned media from RCC cell lines vs normal renal cultures, is a candidate secreted biomarker of RCC
-
Full-text index only
Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases.
PMID 41484106 · PMC12881549 · Nature communications · 2026 · 8 claims · 8 setups
Loss/inhibition of IKKα unexpectedly promotes, rather than suppresses, CRC liver metastasis in patient-derived organoid (PDO) xenograft models.
-
Has reproduction · 54
Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
PMID 37190091 · PMC10137100 · Cells · 2023 · 8 claims · 8 setups
Single-cell transcriptomic analysis of EPCAM+Lin- epithelial cells identified unique gene signatures/markers that distinguish ER+, HER2+, ER+HER2+, and TNBC molecular subtypes
-
Full-text index only
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.
PMID 41820368 · PMC13121600 · Nature communications · 2026 · 8 claims · 8 setups
CBFB (CBF-β) is a synthetic lethal interactor of VHL in ccRCC cell lines
-
Full-text index only
YAP1 Dysfunction Promotes Molecular Properties Linked to Breast Cancer Susceptibility.
PMID 41431390 · PMC13040214 · Cancer prevention research (Philadelphia, Pa.) · 2026 · 7 claims · 8 setups
YAP1 nuclear localization and mRNA expression significantly increase in luminal epithelial cells (LEp) with increased age and with genetic risk for breast cancer (e.g., BRCA1/2 mutation carriers)